ArticleAlzheimer's research & therapy2015
Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Article in Alzheimer's research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Chronic obstructive pulmonary disease as a risk factor for cognitive impairment: a systematic review and meta-analysis.BMJ open respiratory research · 2024Pooled it
- Impact of early glymphatic disorders on the development of vascular dementia.BMC medical imaging · 2026Article
- Amyloid burden, brain metabolism, and gray matter volume in SuperAgers.Arquivos de neuro-psiquiatria · 2026Article
- Specificity of functional network connectivity during the AD prodromal phase in mild cognitive impairment.Frontiers in psychiatry · 2025Article
- Openness and age influence cognitive progression: a longitudinal study.Arquivos de neuro-psiquiatria · 2023Article
- Language Differences Among Individuals with Normal Cognition, Amnestic and Non-Amnestic MCI, and Alzheimer's Disease.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2023Article
- Cerebro-spinal fluid glucose and lactate concentrations changes in response to therapies in patIents with primary brain injury: the START-TRIP study.Critical care (London, England) · 2023Article
- The characteristics of glucose metabolism and functional connectivity in posterior default network during nondemented aging: relationship with executive function performance.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Early screening model for mild cognitive impairment based on resting-state functional connectivity: a functional near-infrared spectroscopy study.Neurophotonics · 2022Article
- Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2022Article
- Increased both cortical activation and functional connectivity after transcranial direct current stimulation in patients with post-stroke: A functional near-infrared spectroscopy study.Frontiers in psychiatry · 2022Article
- The Influence of MTHFR Polymorphism on Gray Matter Volume in Patients With Amnestic Mild Cognitive Impairment.Frontiers in neuroscience · 2021Article
- Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.European journal of nuclear medicine and molecular imaging · 2020Article
- [¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment.Journal of clinical neurology (Seoul, Korea) · 2020Article
- Early Diagnosis of Mild Cognitive Impairment Based on Eye Movement Parameters in an Aging Chinese Population.Frontiers in aging neuroscience · 2020Article
- Memory Performance Correlates of Hippocampal Subfield Volume in Mild Cognitive Impairment Subtype.Frontiers in behavioral neuroscience · 2019Article
- Faulty Adaptation to Repeated Face-Name Associative Pairs in Mild Cognitive Impairment is Predictive of Cognitive Decline.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2018Article
- Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training.Current Alzheimer research · 2018Article
- Alzheimer's Disease, Oligomers, and Inflammation.Journal of Alzheimer's disease : JAD · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosis as compared to amnestic subtypes of MCI (aMCI). Unfortunately, studies investigating biomarker profiles of naMCI are scarce. The study objective was to investigate the regional brain glucose metabolism (rBGM) with [18F]FDG-PET and cerebrospinal fluid (CSF) biomarkers in subjects with naMCI as compared to a control group (CG) and aMCI subjects.
methodsNinety-five patients were included in three different groups: naMCI (N = 32), aMCI (N = 33) and CG (N = 30). Patients underwent brain MRI and [18F]FDG-PET. A subsample (naMCI = 26, aMCI = 28) also had an assessment of amyloid-β, tau, and phosphorylated tau levels in the CSF.
resultsBoth MCI groups had lower rBGM in relation to the CG in the precuneus. Subjects with naMCI showed decreased right prefrontal metabolism as well as higher levels of CSF amyloid-β relative to aMCI subjects.
conclusionWhile amnestic MCI subjects showed a biomarker profile classically related to MCI due to Alzheimer's disease, naMCI patients illustrated a decrease in both prefrontal hypometabolism and higher CSF amyloid-β levels relative to the aMCI group. These biomarker findings indicate that naMCI is probably a heterogeneous group with similar precuneus hypometabolism compared to aMCI, but additional frontal hypometabolism and less amyloid-β deposition in the brain. Clinical follow-up and reappraisal of biomarkers of the naMCI group is needed to determine the outcome and probable etiological diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.